Journal of Pharmacological Sciences
Online ISSN : 1347-8648
Print ISSN : 1347-8613
ISSN-L : 1347-8613
Full Paper
Evaluation of the Therapeutic Index of a Novel Phosphodiesterase 4B–Selective Inhibitor Over Phosphodiesterase 4D in Mice
Osamu SuzukiKiyoshi MizukamiMaki EtoriYoshitaka SogawaNana TakagiHiroshi TsuchidaKiyoshi MorimotoTaiji GotoToshiharu YoshinoTsuyoshi MikkaichiKazuki HiraharaSatoshi NakamuraHiroaki Maeda
Author information
JOURNAL FREE ACCESS

2013 Volume 123 Issue 3 Pages 219-226

Details
Abstract

Phosphodiesterase 4 (PDE4) inhibitors have been developed for the treatment of pulmonary inflammatory diseases, but their clinical use was dose-limited by mainly gastric adverse effects. Recent studies suggested PDE4B-selective inhibitors over PDE4D are supposed to display a wider therapeutic index than subtype non-selective PDE4 inhibitors such as roflumilast. Compound A was identified as an orally active PDE4B-selective inhibitor over PDE4D both in humans (80-fold selective) and mice (29-fold selective). In this study, the therapeutic effects of compound A and roflumilast were evaluated on lipopolysaccaride (LPS) injection–induced plasma TNF-α elevation and on LPS inhalation–induced pulmonary neutrophilia in mice. The inhibitory effect on gastric emptying in mice was evaluated as a gastric adverse effect. The therapeutic index for TNF-α production (TITNF = ID50 in gastric emptying / ID50 in LPS injection–induced plasma TNF-α elevation) of compound A was larger than roflumilast (9.0 and 0.2, respectively), whereas the therapeutic index for pulmonary neutrophilia (TINeu = ID50 in gastric emptying / ID50 in LPS inhalation–induced pulmonary neutrophilia) of compound A was comparable to roflumilast (1.0 and 0.5, respectively). In conclusion, the TINeu of compound A was not superior compared to that of roflumilast in spite of its high selectivity for PDE4B over PDE4D in mice.

Information related to the author
© 2013 The Japanese Pharmacological Society
Previous article Next article
feedback
Top